Ethical issues in clinical research: An issue for all internists

American Journal of Medicine

Volumn 109, Issue 1, 2000, Pages 82-85

  Wolf, Leslie E ^a   Lo, Bernard ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORNITHINE CARBAMOYLTRANSFERASE;

ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DOCTOR PATIENT RELATION; DRUG INDUSTRY; ENZYME DEFICIENCY; ETHICS; GENE THERAPY; HUMAN; MEDICAL RESEARCH; PATIENT INFORMATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; ATTITUDE TO HEALTH; BIOMEDICAL AND BEHAVIORAL RESEARCH; CONFLICT OF INTEREST; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL SCHOOL; MEDICAL SOCIETY; RESEARCH; REVIEW; STANDARD;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

CONFLICT OF INTEREST; ETHICS, MEDICAL; FACULTY, MEDICAL; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERNSHIP AND RESIDENCY; PHYSICIAN-PATIENT RELATIONS; RESEARCH; SOCIETIES, MEDICAL;

EID: 0034220586     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(00)00465-4     Document Type: Note

References (29)

1. Stolberg SG. The biotech death of Jesse Gelsinger. New York Times. November 28, 1999; Sunday Magazine:137.
2. Marshall E. Gene therapy death prompts review of adenovirus vector. Science. 286:1999;2244-2245.
3. Stolberg SG. Biomedicine is receiving new scrutiny as scientists become entrepreneurs. New York Times. February 20, 2000;26.
4. Eichenwald K, Kolata G. Drug trials hide conflicts for doctors. New York Times. May 16, 1999;1.
5. Federal Document Clearing House Political Transcripts. February 2, 2000.
6. Stolberg SG. A death puts gene therapy under increasing scrutiny. New York Times. November 4, 1999;A24.
7. Stolberg SG. Gene therapy ordered halted at university. New York Times. January 22, 2000;A1.
8. Stolberg SG. Teenager's death is shaking up field of gene-therapy experiments. New York Times. January 27, 2000;A20.
9. Appelbaum P.S., Roth L.H., Lidz C.W., et al. False hopes and best data consent to research and the therapeutic misconception. Hastings Center Report. 17:(2):1987;20-24.
10. Kass N.E., Sugarman J., Faden R., Schoch-Spana M. Trust, the fragile foundation of contemporary biomedical research. Hastings Center Report. 26:(5):1996;25-29.
11. Relman A. Economic incentives in clinical investigation. NEJM. 320:1989;933-934.
12. Thompson D. Understanding financial conflicts of interest. NEJM. 329:1993;573-576.
13. Nelson D, Weiss R. Hasty decisions in the race to a cure? Gene therapy study proceeded despite safety, ethics concerns. Washington Post. November 21, 1999;A1.
14. Whitaker R. Doing harm: research on the mentally ill. Boston Globe. November 17, 1998;A1.
15. Rettig R.A. The industrialization of clinical research. Health Affairs. 19:2000;129-146.
16. United States Advisory Committee on Human Radiation Experiments. Final Report. 1995;US Government Printing Office, Washington, DC.
17. Lo B. Ethical issues in clinical research. In: Hulley S, ed. Designing Clinical Research. 2nd ed. Philadelphia: JB Lippincott; 2000.
18. Eichenwald K, Kolata G. A doctor's drug trials turn into fraud. New York Times. May 17, 1999;A1.
19. Angell M., Kassirer J. Setting the record straight in the breast-cancer trials. NEJM. 330:1994;1448-1450.
20. Culliton B. Coping with fraud the Darsee case. Science. 220:1983;31-35.
21. Engler R., Covell J., Friendman P., et al. Misrepresentation and responsibility in medical research. NEJM. 317:1987;1383-1389.
22. Relman A. Lessons from the Darsee affair. NEJM. 308:1983;1415-1417.
23. Stolberg SG. FDA officials fault Penn team in gene therapy death. New York Times. December 9, 1999;A22.
24. Lo B. Overview of conflicts of interest. In: Resolving Ethical Dilemmas: A Guide for Clinicians. 2nd ed. Philadelphia: JB Lippincott; 2000.
25. Hillman A.L., Eisenberg J.M., Pauly M.V., et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. NEJM. 324:1991;1362-1365.
26. Rennie D. Thyroid storm. JAMA. 277:1997;1238-1243.
27. Moore v. Regents of University of California, 793 P.2d 479 (Cal. 1990).
28. Topol E.J., Armstrong P., van de Werf F., et al. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. J Am Coll Cardiol. 19:1992;1123-1128.
29. Healy B., Campeau L., Gray R., et al. Conflict-of-interest guidelines for a multicenter clinical trial of treatment after coronary-artery bypass-graft surgery. NEJM. 320:1989;949-951.